A drug developed by a joint venture between Samsung Biologics and Biogen Inc. was recommended for approval by the European Union’s drug regulator, threatening sales of a similar Pfizer Inc. product.
The drug, to be marketed as Benepali, is a version of Enbrel, a rheumatoid arthritis and psoriasis treatment sold by Pfizer in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting of a marketing authorization for Benepali, joint venture Samsung Bioepis said in a statement on Friday.
